Replies to post #4637 on Antares Pharma, Inc. (ATRS)

[ou71764]

Thanks for the link. If the market grows, whatever piece Xyosted gets will be bigger. But given the most recent Rx numbers for Xyosted, we don't seem to be gaining market share as fast as I thought we would. I won't be eager to see a competitor get approved for an oral therapy if we're only seeing incremental gains instead of accelerating.

I still think ATRS is underpriced in its totality. It's more than just Xyosted. I'm hoping for an upbeat conference call on Tuesday so we can get the stock price moving upward again.